Scinovex
articleTop 1% cited

Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

Breast Cancer Research and Treatment · 2001 · Vol. 65(2) · pp. 125–134
Jane A. CauleyLarry NortonMarc E. LippmanStephen EckertK A KruegerDavid W PurdieJordi FarreronsAvraham KarasikDan MellströmKong Wah NgJ ŠtěpánTrevor J. PowlesMonica MorrowAlberto CostaSheryl L. SilfenErin L. WallsHenry SchmittDouglas B. MuchmoreV. Craig Jordan
Estrogen and related hormone effectsCancer Risks and FactorsBreast Cancer Treatment StudiesRaloxifeneMedicineBreast cancerSelective estrogen receptor modulatorOsteoporosisTamoxifenPlaceboGynecologyRelative riskInternal medicine

MeSH terms

AgedAged, 80 and overAustraliaBreast NeoplasmsDouble-Blind MethodEstrogen AntagonistsEuropeFemaleFollow-Up StudiesHumansMammographyMiddle AgedNew ZealandRisk FactorsUnited States

Funding

  • Eli Lilly and Company
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial · Scinovex